318 related articles for article (PubMed ID: 24758484)
1. Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer.
Zhang ZD; Kong Y; Yang W; Zhang B; Zhang YL; Ma EM; Liu HX; Chen XB; Hua YW
World J Surg Oncol; 2014 Apr; 12():115. PubMed ID: 24758484
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer.
Bando H; Yamada Y; Tanabe S; Nishikawa K; Gotoh M; Sugimoto N; Nishina T; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Miwa H; Hamada C; Hyodo I
Gastric Cancer; 2016 Jul; 19(3):919-26. PubMed ID: 26474989
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study).
Koizumi W; Takiuchi H; Yamada Y; Boku N; Fuse N; Muro K; Komatsu Y; Tsuburaya A
Ann Oncol; 2010 May; 21(5):1001-5. PubMed ID: 19875759
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients.
Dai X; Zhang X; Wang C; Jiang J; Wu C
Oncotarget; 2017 May; 8(18):30495-30501. PubMed ID: 27911869
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).
Boku N; Ryu MH; Kato K; Chung HC; Minashi K; Lee KW; Cho H; Kang WK; Komatsu Y; Tsuda M; Yamaguchi K; Hara H; Fumita S; Azuma M; Chen LT; Kang YK
Ann Oncol; 2019 Feb; 30(2):250-258. PubMed ID: 30566590
[TBL] [Abstract][Full Text] [Related]
6. Combination Chemotherapy with S-1 and Oxaliplatin (SOX) as First-Line Treatment in Elderly Patients with Advanced Gastric Cancer.
Zhong DT; Wu RP; Wang XL; Huang XB; Lin MX; Lan YQ; Chen Q
Pathol Oncol Res; 2015 Sep; 21(4):867-73. PubMed ID: 25648439
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer.
Nakayama N; Ishido K; Chin K; Nishimura K; Azuma M; Matsusaka S; Inokuchi Y; Tanabe S; Kumekawa Y; Koizumi W
Gastric Cancer; 2017 Mar; 20(2):350-357. PubMed ID: 27189323
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases.
Shi M; Yang Z; Lu S; Liu W; Ni Z; Yao X; Hua Z; Feng R; Zheng Y; Wang Z; Sah BK; Chen M; Zhu Z; He C; Li C; Zhang J; Yan C; Yan M; Zhu Z
BMC Cancer; 2021 Dec; 21(1):1344. PubMed ID: 34922478
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma.
Lee DW; Lee KH; Kim HJ; Kim TY; Kim JS; Han SW; Oh DY; Kim JH; Im SA; Kim TY
BMC Cancer; 2018 Mar; 18(1):252. PubMed ID: 29506478
[TBL] [Abstract][Full Text] [Related]
10. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
11. [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
Wan Y; Hui H; Wang X; Wu J; Sun S
Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):28-34. PubMed ID: 26796803
[TBL] [Abstract][Full Text] [Related]
12. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
Kim GM; Jeung HC; Rha SY; Kim HS; Jung I; Nam BH; Lee KH; Chung HC
Eur J Cancer; 2012 Mar; 48(4):518-26. PubMed ID: 22243774
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II study comparing paclitaxel with S-1 vs. S-1 as first-line treatment in patients with advanced gastric cancer.
Wang X; Wang ML; Zhou LY; Lu XY; Yang JF; Yu HG
Clin Transl Oncol; 2013 Oct; 15(10):836-42. PubMed ID: 23381898
[TBL] [Abstract][Full Text] [Related]
15. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer.
Han SW; Oh DY; Im SA; Park SR; Lee KW; Song HS; Lee NS; Lee KH; Choi IS; Lee MH; Kim MA; Kim WH; Bang YJ; Kim TY
Br J Cancer; 2009 Jan; 100(2):298-304. PubMed ID: 19127259
[TBL] [Abstract][Full Text] [Related]
16. S-1 combined with oxaliplatin as first line chemotherapy for Chinese advanced gastric cancer patients.
Liu B; Ying J; Luo C; Xu Q; Zhu L; Zhong H
Hepatogastroenterology; 2012; 59(114):649-53. PubMed ID: 22328264
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer.
Oh SY; Kwon HC; Jeong SH; Joo YT; Lee YJ; Cho Sh; Kang MH; Go SI; Lee GW; Kim Hg; Kang JH
Invest New Drugs; 2012 Feb; 30(1):350-6. PubMed ID: 20706861
[TBL] [Abstract][Full Text] [Related]
18. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
[No Abstract] [Full Text] [Related]
19. Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study.
Jiang Z; Zhou A; Sun Y; Zhang W
BMC Cancer; 2022 Mar; 22(1):253. PubMed ID: 35264150
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of biweekly oxaliplatin plus S-1 combination chemotherapy as a first-line treatment for patients with metastatic or advanced gastric cancer in China.
Xiao C; Qian J; Zheng Y; Song F; Wang Q; Jiang H; Mao C; Xu N
Medicine (Baltimore); 2019 May; 98(20):e15696. PubMed ID: 31096513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
